Surrogate SARS-CoV-2 Neutralization Assay Kit
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting SARS-CoV-2 antibodies are either expensive, time-consuming, and pose biosafety risks, and existing ELISA tests suffer from specificity issues, limiting their use in surveillance beyond human species and requiring confirmation with more reliable but costly virus neutralization tests.
Innovation Solution
A kit and method using surrogate molecules, specifically the spike protein or ACE2 protein, conjugated to detection entities, immobilized on solid supports, to detect neutralizing antibodies by mimicking the virus-host interaction, allowing for rapid, specific, and species-independent detection without the need for live viruses or BSL3 facilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If virus neutralization test (VNT) is used as the gold standard, then reliability and specificity are improved, but cost, time consumption, and biosafety risks increase
Solution Approach 1:
The invention extracts the essential functional interaction from the complex live virus system. Instead of using complete live SARS-CoV-2 viruses in BSL3 facilities, the patent isolates and uses only the spike protein (specifically the receptor-binding domain RBD) as a surrogate antigen. This extraction maintains the critical virus-ACE2 interaction mechanism while eliminating the need for complex biosafety infrastructure, allowing tests to be performed in BSL2 or even BSL1 laboratories.
Solution Approach 2:
The invention creates a simplified copy or surrogate model of the virus neutralization test. The surrogate VNT uses recombinant spike protein RBD conjugated to carrier proteins (such as keyhole limpet hemocyanin or ferritin) to mimic the neutralization process. This copied system reproduces the essential immunological interaction without requiring live virus, thereby maintaining reliability while reducing complexity and safety requirements.
2Ease of operation
If conventional ELISA is used for screening, then ease of operation and cost are improved, but measurement precision and reliability deteriorate due to specificity issues
Solution Approach 1:
The invention applies local quality by focusing the ELISA assay on a specific, highly relevant epitope - the spike protein RBD region that directly interacts with ACE2. Instead of using whole virus or non-specific antigens, the patent concentrates the antigenic target on the precise functional domain responsible for neutralization. This localized approach maintains ELISA simplicity while dramatically improving specificity, as antibodies detected are those that bind to the critical neutralization target.
Solution Approach 2:
The invention introduces an intermediary element - the recombinant spike protein RBD conjugated to a carrier protein - that mediates between the simple ELISA format and the complex neutralization test. The conjugated RBD acts as a bridge, providing the specific immunological target needed for accurate neutralization detection while maintaining the ease of ELISA operation. The carrier protein enhances immunogenicity without compromising specificity.
3Measurement precision
If species-specific ELISA is developed for each wildlife species, then measurement precision is improved, but device complexity and development time increase significantly
Solution Approach 1:
The invention achieves universality by using the conserved spike protein RBD structure as the antigen across all species surveys. The recombinant RBD conjugated to universal carriers (such as ferritin or KLH) can detect neutralizing antibodies in any species that has been infected with SARS-CoV-2 or related coronaviruses. This single universal assay replaces the need for developing multiple species-specific ELISAs, enabling broad wildlife surveillance while maintaining detection precision through the conserved functional domain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a reliable, sensitive, and specific method for detecting neutralizing antibodies across various species, reducing costs and biosafety concerns, enabling rapid results without the need for live virus handling, thus addressing the limitations of existing assays.
Implementation Method 1
a polypeptide which binds specifically to the polypeptide or fragment of (i)
Implementation Method 2
the spike protein or fragment of (i) or the ACE2 protein or fragment of (ii) may be conjugated to a detection entity
Implementation Method 3
the spike protein or fragment of (i) or the ACE2 protein or fragment of (ii) may be immobilised on a solid support
Data Source
AI summary
A kit, composition and method for detection of antibodies to severe acute respiratory syndrome related coronavirus (SARSr-CoV), and for diagnosis of SARSr-CoV infection.